NEW YORK (GenomeWeb) — Cepheid's high-burden developing country (HBDC) program — the initiative through which it sells its GeneXpert system and related tuberculosis/drug-resistance test to resource-poor territories at a subsidized, discounted price — continues to serve as an important revenue driver at the company.

The Sunnyvale, Calif.-based MDx firm said last week that its first quarter revenues grew 16 percent year over year to $106.9 million, driven in no small part by 69 percent growth in its HBDC program to $18.3 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: issues in reproducibility, circulating DNA predicts breast cancer relapse, and more.

Because of an autoimmune disorder, a man has been shedding live polioviruses for 28 years, according to an analysis appearing in PLOS Pathogens.

Being in a long-term collaboration can increase researchers' citation rates by 17 percent, a recent analysis says.

By analyzing tweets, Canadian researchers examine the public's view of gene patenting.